Published in Nat Genet on July 01, 1996
Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med (2009) 10.01
Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map. Proc Natl Acad Sci U S A (1997) 5.61
Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J (1999) 5.49
TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J (1997) 4.48
Targeted disruption of Smad3 reveals an essential role in transforming growth factor beta-mediated signal transduction. Mol Cell Biol (1999) 3.55
Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes. Genes Dev (1997) 3.33
Prevalence of somatic alterations in the colorectal cancer cell genome. Proc Natl Acad Sci U S A (2002) 3.25
Transforming growth factor beta-induced phosphorylation of Smad3 is required for growth inhibition and transcriptional induction in epithelial cells. Proc Natl Acad Sci U S A (1997) 2.97
15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci U S A (2004) 2.42
Smad proteins exist as monomers in vivo and undergo homo- and hetero-oligomerization upon activation by serine/threonine kinase receptors. EMBO J (1998) 2.20
Vascular MADs: two novel MAD-related genes selectively inducible by flow in human vascular endothelium. Proc Natl Acad Sci U S A (1997) 2.15
Role of TAK1 and TAB1 in BMP signaling in early Xenopus development. EMBO J (1998) 2.15
Mouse models for the study of colon carcinogenesis. Carcinogenesis (2008) 2.10
Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci U S A (1997) 1.76
Mechanisms underlying losses of heterozygosity in human colorectal cancers. Proc Natl Acad Sci U S A (2001) 1.68
SMAD4 mutations in colorectal cancer probably occur before chromosomal instability, but after divergence of the microsatellite instability pathway. Proc Natl Acad Sci U S A (2001) 1.65
Targeted deletion of Smad4 shows it is required for transforming growth factor beta and activin signaling in colorectal cancer cells. Proc Natl Acad Sci U S A (1998) 1.55
Regulation of transforming growth factor beta- and activin-induced transcription by mammalian Mad proteins. Proc Natl Acad Sci U S A (1996) 1.46
The CDKN2A (p16) gene and human cancer. Mol Med (1997) 1.46
Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A (2000) 1.43
Postgastrulation Smad2-deficient embryos show defects in embryo turning and anterior morphogenesis. Proc Natl Acad Sci U S A (1999) 1.41
Genomic instability is an early event during the progression pathway of ulcerative-colitis-related neoplasia. Am J Pathol (1999) 1.35
Promoting bone morphogenetic protein signaling through negative regulation of inhibitory Smads. EMBO J (2001) 1.34
Smad4 inactivation promotes malignancy and drug resistance of colon cancer. Cancer Res (2011) 1.28
Expression of Wnt ligands and Frizzled receptors in colonic mucosa and in colon carcinoma. Mol Pathol (2002) 1.25
DEC1 is a downstream target of TGF-beta with sequence-specific transcriptional repressor activities. Proc Natl Acad Sci U S A (2002) 1.24
TGFβ Signaling in Tumor Initiation, Epithelial-to-Mesenchymal Transition, and Metastasis. J Oncol (2015) 1.23
Schistosoma mansoni: TGF-beta signaling pathways. Exp Parasitol (2007) 1.15
Genetic epidemiology of mutated K-ras proto-oncogene, altered suppressor genes, and microsatellite instability in colorectal adenomas. Gut (1999) 1.13
Transforming growth factor-beta and breast cancer: Transforming growth factor-beta/SMAD signaling defects and cancer. Breast Cancer Res (2000) 1.11
Identifying disease genes and module biomarkers by differential interactions. J Am Med Inform Assoc (2011) 1.07
Transgenic analysis of the Smad family of TGF-beta signal transducers in Drosophila melanogaster suggests new roles and new interactions between family members. Genetics (2001) 1.01
Two sides of the story? Smad4 loss in pancreatic cancer versus head-and-neck cancer. FEBS Lett (2012) 0.98
Immunohistochemical analysis of adenocarcinoma of the small intestine: a tissue microarray study. J Clin Pathol (2003) 0.97
Role of TGFβ in regulation of the tumor microenvironment and drug delivery (review). Int J Oncol (2015) 0.96
Colorectal cancer: chemopreventive role of curcumin and resveratrol. Nutr Cancer (2010) 0.96
Mapping of genetic deletions on the long arm of chromosome 4 in human esophageal adenocarcinomas. Am J Pathol (1999) 0.96
The tale of transforming growth factor-beta (TGFbeta) signaling: a soigné enigma. IUBMB Life (2009) 0.96
AGR2 is a SMAD4-suppressible gene that modulates MUC1 levels and promotes the initiation and progression of pancreatic intraepithelial neoplasia. Oncogene (2012) 0.95
TGF-beta signaling in colon cancer cells. World J Surg (2005) 0.93
Dietary fiber enhances a tumor suppressor signaling pathway in the gut. Ann Surg (2006) 0.91
Somatic alterations of the SMAD-2 gene in human colorectal cancers. Br J Cancer (1998) 0.89
The revised role of TGF-β in aortic aneurysms in Marfan syndrome. Neth Heart J (2015) 0.89
Growth-promoting effect of muscarinic acetylcholine receptors in colon cancer cells. J Cancer Res Clin Oncol (2003) 0.88
The Notch ligand Delta-like 1 integrates inputs from TGFbeta/Activin and Wnt pathways. Exp Cell Res (2011) 0.88
Regulation of metastasis in colorectal adenocarcinoma: a collision between development and tumor biology. Surgery (2008) 0.87
Dietary fiber enhances TGF-β signaling and growth inhibition in the gut. Am J Physiol Gastrointest Liver Physiol (2011) 0.85
SMAD4--molecular gladiator of the TGF-beta signaling is trampled upon by mutational insufficiency in colorectal carcinoma of Kashmiri population: an analysis with relation to KRAS proto-oncogene. BMC Cancer (2010) 0.84
Sequence and chromosomal mapping of the mouse homolog (Madh4) of the human DPC4/MADH4 gene. Mamm Genome (1997) 0.81
Use of bone morphogenetic proteins in mesenchymal stem cell stimulation of cartilage and bone repair. World J Stem Cells (2016) 0.81
Overexpression of c-erbB-2 protein correlates with chromosomal gain at the c-erbB-2 locus and patient survival in advanced colorectal carcinomas. Clin Exp Metastasis (2002) 0.80
Smad4 (DPC4)--a potent tumour suppressor? Br J Cancer (1998) 0.80
Bone morphogenetic proteins and their antagonists: current and emerging clinical uses. Br J Pharmacol (2014) 0.79
Abrogation of transforming growth factor-beta signaling in pancreatic cancer. World J Surg (2005) 0.79
Epstein-Barr virus BARF1-induced NFκB/miR-146a/SMAD4 alterations in stomach cancer cells. Oncotarget (2016) 0.78
Evaluation of the colorectal cancer risk conferred by rare UNC5C alleles. World J Gastroenterol (2014) 0.77
Transforming Growth Factor β Superfamily Signaling in Development of Colorectal Cancer. Gastroenterology (2016) 0.77
The genomics of colorectal cancer: state of the art. Curr Genomics (2008) 0.76
Genomic Analysis of the BMP Family in Glioblastomas. Transl Oncogenomics (2015) 0.75
MicroRNA-23a regulates epithelial-to-mesenchymal transition in endometrial endometrioid adenocarcinoma by targeting SMAD3. Cancer Cell Int (2016) 0.75
Prognostic value of loss of heterozygosity and sub-cellular localization of SMAD4 varies with tumor stage in colorectal cancer. Oncotarget (2017) 0.75
Mutation and expression of the DCC gene in human lung cancer. Neoplasia (2001) 0.75
A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem (1983) 206.01
"A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity". Addendum. Anal Biochem (1984) 66.58
Serial analysis of gene expression. Science (1995) 60.15
A genetic model for colorectal tumorigenesis. Cell (1990) 44.37
WAF1, a potential mediator of p53 tumor suppression. Cell (1993) 38.72
Surfing the p53 network. Nature (2000) 35.36
p53 mutations in human cancers. Science (1991) 31.96
Preparative and analytical purification of DNA from agarose. Proc Natl Acad Sci U S A (1979) 27.20
Genetic alterations during colorectal-tumor development. N Engl J Med (1988) 26.82
Lessons from hereditary colorectal cancer. Cell (1996) 25.73
Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science (1997) 24.61
A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A (1998) 24.58
Identification of c-MYC as a target of the APC pathway. Science (1998) 24.25
Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science (1997) 22.80
Genetic instabilities in human cancers. Nature (1998) 22.76
A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell (1992) 19.87
Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science (1998) 17.91
Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature (1992) 17.40
Participation of p53 protein in the cellular response to DNA damage. Cancer Res (1991) 16.00
Clues to the pathogenesis of familial colorectal cancer. Science (1993) 14.52
Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science (1995) 13.15
Definition of a consensus binding site for p53. Nat Genet (1992) 12.76
Genetic instability in colorectal cancers. Nature (1997) 12.51
Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science (1989) 11.53
Identification of FAP locus genes from chromosome 5q21. Science (1991) 11.41
A model for p53-induced apoptosis. Nature (1997) 11.38
Characterization of the yeast transcriptome. Cell (1997) 11.33
Mutations of mitotic checkpoint genes in human cancers. Nature (1998) 11.20
Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (1990) 11.18
DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science (1996) 11.13
Genes expressed in human tumor endothelium. Science (2000) 10.75
Digital PCR. Proc Natl Acad Sci U S A (1999) 10.54
Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science (1992) 10.12
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A (1998) 9.66
Gene expression profiles in normal and cancer cells. Science (1997) 9.65
APC mutations occur early during colorectal tumorigenesis. Nature (1992) 9.50
Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature (1983) 9.28
Prevalence of ras gene mutations in human colorectal cancers. Nature (1987) 9.23
A public database for gene expression in human cancers. Cancer Res (1999) 8.81
Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet (1994) 8.34
Identification of a chromosome 18q gene that is altered in colorectal cancers. Science (1990) 8.32
Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol (1983) 8.24
PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell (2001) 7.95
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature (1993) 7.90
p53 function and dysfunction. Cell (1992) 7.73
14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell (1997) 7.20
Association of the APC tumor suppressor protein with catenins. Science (1993) 7.17
Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A (1987) 7.12
Oncogenic forms of p53 inhibit p53-regulated gene expression. Science (1992) 6.73
p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res (1995) 6.66
Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell (1993) 6.61